Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 8/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 8/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20526950 | 0.83 | IGLV6-57 (0.51) | IGLV6-57KCNH2 | |
| SCHEMBL13577180 | 0.81 | IGLV6-57 (0.51) | FFAR1LTB4RLTB4R2ALOX5IGLV6-57 | |
| SCHEMBL13577130 | 0.79 | ALOX5 (0.47) | FFAR1LTB4RLTB4R2ALOX5IGLV6-57 | |
| SCHEMBL13577129 | 0.79 | ALOX5 (0.47) | FFAR1LTB4RLTB4R2ALOX5IGLV6-57 | |
| SCHEMBL13577011 | 0.79 | ALOX5 (0.47) | FFAR1LTB4RLTB4R2ALOX5IGLV6-57 | |
| SCHEMBL13577006 | 0.79 | ALOX5 (0.47) | FFAR1LTB4RLTB4R2ALOX5IGLV6-57 | |
| SCHEMBL6904351 | 0.75 | FFAR1 (0.61) | FFAR1LTB4RLTB4R2ALOX5IGLV6-57 | |
| SCHEMBL18398373 | 0.75 | HDAC3 (0.42) | — | |
| SCHEMBL14114020 | 0.75 | FFAR1 (0.62) | FFAR1LTB4RLTB4R2ALOX5S1PR5 | |
| SCHEMBL11250901 | 0.74 | ALOX5 (0.54) | FFAR1LTB4RLTB4R2ALOX5IGLV6-57 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-07-21 | — | — | US | disclosed |
| CN-108430994-B | Compounds, compositions and methods for modulating CFTR | 蛋白质平衡治疗股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3359536-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-11 | — | — | US | disclosed |
| WO-2017062581-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | FFAR1 2378/4885LTB4R 434/4885LTB4R2 450/4885 |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | FFAR1 2378/4885LTB4R 434/4885LTB4R2 450/4885 |
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | FFAR1 2378/4885LTB4R 434/4885LTB4R2 450/4885 |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | FFAR1 2378/4885LTB4R 434/4885LTB4R2 450/4885 |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | FFAR1 2378/4885LTB4R 434/4885LTB4R2 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.